Business Context and Reporting Period
Company: Inotek Pharmaceuticals Corporation (trading as "ROCKET PHARMACEUTICALS, INC." in the request metadata, though the filing identifies the registrant as Inotek Pharmaceuticals Corporation).
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2014
Business Overview: Inotek is a clinical-stage biopharmaceutical company focused on developing therapies for glaucoma. Its lead product candidate is trabodenoson, a first-in-class selective adenosine mimetic designed to lower intraocular pressure (IOP). The company has no approved products and has not generated any revenue from product sales. As of December 31, 2014, the company had five employees.
Key Financial Metrics
| Financial Metric (in thousands) | 2014 | 2013 | 2012 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(9,531) | $(7,616) | $(6,058) |
| Research & Development Expenses | $(5,592) | $(5,330) | $(3,542) |
| General & Administrative Expenses | $(2,112) | $(1,324) | $(2,307) |
| Cash and Cash Equivalents (Year End) | $3,618 | $12,793 | $1,372 |
| Total Liabilities | $10,278 | $10,525 | $3,789 |
| Stockholders' Deficit | $(51,559) | $(38,895) | $(30,930) |
Liquidity: As of December 31, 2014, the company held $3.6 million in cash. The company reported a significant cash burn, with net cash used in operating activities totaling $9.7 million for 2014.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $1.9 million (25%) from 2013 to 2014, driven by higher operating expenses and non-cash charges related to fair value adjustments.
- Operating Expenses: Total operating expenses rose by $1.05 million to $7.7 million. Research and Development (R&D) expenses increased by $0.26 million, primarily due to higher costs for the Phase 2 trial of the trabodenoson fixed-dose combination (FDC). General and Administrative (G&A) expenses increased by $0.79 million, offset by one-time severance costs in 2013.
- Other Income/Expense: Non-cash expenses related to the change in fair value of warrant liabilities and convertible notes redemption rights derivative increased significantly to $0.85 million in 2014 from $0.08 million in 2013.
- Debt Structure: The company issued $2.0 million in subordinated convertible promissory notes ("2014 Bridge Notes") in December 2014. These notes were subsequently converted into common stock upon the company's Initial Public Offering (IPO) in February 2015.
Guidance, Outlook, and Risks
Recent Capital Raise (Subsequent Event): In February 2015, the company completed an IPO and a concurrent offering of 5.0% Convertible Senior Notes due 2020. The company received net proceeds of approximately $36.6 million from equity and $18.9 million from debt issuances. Management estimates these funds, combined with existing cash, will sustain operations for the next 18 months.
Development Outlook:
- Trabodenoson Monotherapy: The company plans an End-of-Phase 2 meeting with the FDA in the first half of 2015. A Phase 3 program is expected to initiate in mid-2015, with top-line data anticipated in late 2016 or early 2017.
- Fixed-Dose Combination (FDC): Phase 2 trials for the FDC of trabodenoson and latanoprost were completed in 2014, showing efficacy in patients who were poor responders to latanoprost alone. Phase 2 formulation trials are expected to begin in late 2016.
Key Risks:
- Capital Requirements: The company has no revenue and expects to incur significant losses for the foreseeable future. It will require additional financing to complete clinical trials and commercialize products.
- Regulatory Approval: Success depends entirely on obtaining FDA approval for trabodenoson. Clinical trials may fail, or the FDA may require additional studies.
- Competition: The glaucoma market is dominated by generic drugs. The company faces competition from established pharmaceutical companies and new therapies in development.
- Third-Party Reliance: The company relies on third-party manufacturers for clinical supplies and contract research organizations (CROs) for clinical trials.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $55.5 million raised in the February 2015 IPO/Note offering to fund the planned Phase 3 trials through 2017.
- Phase 3 Design: Confirm the outcome of the End-of-Phase 2 meeting with the FDA regarding the design and endpoints of the pivotal Phase 3 trials.
- Debt Covenants: Review the restrictive covenants in the 2020 Convertible Senior Notes indenture, which limit the ability to incur additional indebtedness or issue preferred stock.
- Patent Expiration: Note that composition of matter patents for trabodenoson are scheduled to expire in 2025 (Europe) and 2026 (U.S.), with method-of-use patents extending to 2030-2034.
- Net Operating Losses (NOLs): Assess the impact of the IPO on the company's ability to utilize its $77.1 million in federal NOL carryforwards, as an "ownership change" could limit their use.